Insider Buying: Rapport Therapeutics (NASDAQ:RAPP) CFO Acquires 9,900 Shares of Stock

Rapport Therapeutics (NASDAQ:RAPP) CFO Troy A. Ignelzi acquired 9,900 shares of Rapport Therapeutics stock in a transaction dated Wednesday, March 12th. The shares were acquired at an average price of $10.10 per share, with a total value of $99,990.00. Following the completion of the purchase, the chief financial officer now owns 9,900 shares in the company, valued at approximately $99,990. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

Rapport Therapeutics Price Performance

Rapport Therapeutics stock opened at $10.02 on Friday. Rapport Therapeutics has a 52 week low of $6.43 and a 52 week high of $29.74. The stock has a fifty day moving average of $13.72 and a 200-day moving average of $18.82.

Institutional Investors Weigh In On Rapport Therapeutics

A number of hedge funds have recently made changes to their positions in the business. TRV GP V LLC bought a new stake in Rapport Therapeutics during the 4th quarter worth approximately $126,579,000. FMR LLC lifted its holdings in shares of Rapport Therapeutics by 10.1% in the 3rd quarter. FMR LLC now owns 5,486,468 shares of the company’s stock worth $112,363,000 after acquiring an additional 503,117 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Rapport Therapeutics by 9.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,143,384 shares of the company’s stock worth $20,285,000 after buying an additional 95,976 shares during the period. Alliancebernstein L.P. raised its holdings in Rapport Therapeutics by 0.9% during the 4th quarter. Alliancebernstein L.P. now owns 1,098,415 shares of the company’s stock valued at $19,486,000 after buying an additional 9,494 shares during the last quarter. Finally, TRV GP VI LLC purchased a new stake in shares of Rapport Therapeutics during the fourth quarter worth about $17,194,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.